A detailed history of Wellington Management Group LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 15,566,969 shares of APLS stock, worth $530 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
15,566,969
Previous 16,388,697 5.01%
Holding current value
$530 Million
Previous $629 Million 28.59%
% of portfolio
0.08%
Previous 0.11%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$28.84 - $41.15 $23.7 Million - $33.8 Million
-821,728 Reduced 5.01%
15,566,969 $449 Million
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $50.7 Million - $79.5 Million
1,330,626 Added 8.84%
16,388,697 $629 Million
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $834 Million - $1.09 Billion
15,058,071 New
15,058,071 $885 Million
Q4 2023

Feb 12, 2024

BUY
$37.14 - $64.82 $611 Million - $1.07 Billion
16,445,290 New
16,445,290 $984 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $201 Million - $759 Million
8,502,769 Added 127.59%
15,167,044 $577 Million
Q2 2023

Aug 14, 2023

SELL
$76.68 - $93.31 $124 Million - $151 Million
-1,614,164 Reduced 19.5%
6,664,275 $607 Million
Q1 2023

May 12, 2023

SELL
$46.59 - $66.96 $22.3 Million - $32.1 Million
-479,222 Reduced 5.47%
8,278,439 $546 Million
Q4 2022

Feb 13, 2023

SELL
$43.24 - $61.04 $51.9 Million - $73.2 Million
-1,199,755 Reduced 12.05%
8,757,661 $453 Million
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $71 Million - $110 Million
-1,585,327 Reduced 13.73%
9,957,416 $680 Million
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $93.2 Million - $157 Million
-2,656,551 Reduced 18.71%
11,542,743 $522 Million
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $66.3 Million - $101 Million
1,868,641 Added 15.15%
14,199,294 $721 Million
Q4 2021

Feb 11, 2022

BUY
$30.74 - $49.16 $35.6 Million - $57 Million
1,159,081 Added 10.38%
12,330,653 $583 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $14.4 Million - $32 Million
457,747 Added 4.27%
11,171,572 $368 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $9.23 Million - $14.6 Million
225,721 Added 2.15%
10,713,825 $677 Million
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $816,285 - $1.15 Million
-20,007 Reduced 0.19%
10,488,104 $450 Million
Q4 2020

Feb 12, 2021

BUY
$30.79 - $57.2 $1.7 Million - $3.16 Million
55,303 Added 0.53%
10,508,111 $601 Million
Q3 2020

Nov 16, 2020

BUY
$25.89 - $33.65 $214,809 - $279,194
8,297 Added 0.08%
10,452,808 $315 Million
Q2 2020

Aug 14, 2020

BUY
$24.8 - $38.49 $1.8 Million - $2.79 Million
72,513 Added 0.7%
10,444,511 $341 Million
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $108 Million - $268 Million
6,054,734 Added 140.24%
10,371,998 $278 Million
Q4 2019

Feb 11, 2020

BUY
$22.1 - $30.8 $95.4 Million - $133 Million
4,317,264 New
4,317,264 $132 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.74B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.